| Q46041813 | A multicenter, open-label, 24-week follow-up study for efficacy on cognitive function of donepezil in Binswanger-type subcortical vascular dementia |
| Q45160988 | A randomized controlled trial of the group reminiscence approach in patients with vascular dementia |
| Q47955004 | Acetylcholinesterase inhibitors and the risk of hip fracture in Alzheimer's disease patients: a case-control study |
| Q47271868 | Acetylcholinesterase inhibitors and the risk of osteoporotic fractures: nested case-control study |
| Q51900860 | Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention. |
| Q38386224 | Aerobic exercise and vascular cognitive impairment: A randomized controlled trial. |
| Q35996331 | Agreement between Patient and Proxy Assessments of Quality of Life among Older Adults with Vascular Cognitive Impairment Using the EQ-5D-3L and ICECAP-O |
| Q38780332 | Alzheimer's disease with cerebrovascular disease: current status in the Asia-Pacific region |
| Q34038332 | An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patients |
| Q34095488 | Anti-inflammatory and anti-thrombogenic effects of atorvastatin in acute ischemic stroke |
| Q36846711 | Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease |
| Q30848732 | Binswanger's disease: toward a diagnosis agreement and therapeutic approach |
| Q37217895 | Cholinergic components of frontal lobe function and dysfunction |
| Q33552656 | Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment |
| Q57579201 | Cholinergic dysfunction in subcortical ischaemic vascular dementia: a transcranial magnetic stimulation study |
| Q36046170 | Cholinergic dysfunction in vascular dementia |
| Q35631400 | Cholinesterase inhibitors and vascular dementia: another string to their bow? |
| Q35565715 | Cholinesterase inhibitors for vascular dementia? |
| Q33238993 | Cholinesterase inhibitors: drugs looking for a disease? |
| Q46480727 | Clinical and therapeutic aspects of vascular dementia |
| Q92671707 | Clinical practice guideline for cognitive impairment of cerebral small vessel disease |
| Q36632771 | Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology |
| Q64076387 | Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: systematic review and Bayesian network meta-analysis |
| Q37644400 | Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia. |
| Q37543915 | Current concepts in vascular cognitive impairment and pharmacotherapeutic implications |
| Q33160127 | Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials. |
| Q36249979 | Dementia with cerebrovascular disease: the benefits of early treatment |
| Q37049665 | Diagnosis and management of vascular cognitive impairment |
| Q84966477 | Diagnosis and treatment of subcortical vascular dementia |
| Q30436664 | Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions |
| Q24247449 | Donepezil for vascular cognitive impairment |
| Q34965949 | Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics |
| Q40120849 | Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. |
| Q80379056 | Donepezil in vascular dementia : a neurosonological and neuropsychological study |
| Q46726995 | Donepezil in vascular dementia: combined analysis of two large-scale clinical trials |
| Q51846639 | Donepezil treatment in Alzheimer's disease patients with and without cerebrovascular lesions: a preliminary report. |
| Q36544994 | Donepezil: a review |
| Q36808057 | Donepezil: an update |
| Q35598667 | Donepezil: in vascular dementia |
| Q42083636 | Effect of Attention Training in Mild Cognitive Impairment Patients with Subcortical Vascular Changes: The RehAtt Study |
| Q89594423 | Effect of acetylcholinesterase inhibitors on post-stroke cognitive impairment and vascular dementia: A meta-analysis |
| Q35049086 | Effect of oral administration of zanapezil (TAK-147) for 21 days on acetylcholine and monoamines levels in the ventral hippocampus of freely moving rats |
| Q33980960 | Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease |
| Q34661480 | Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials |
| Q36131600 | Efficacy and safety assessment of acupuncture and nimodipine to treat mild cognitive impairment after cerebral infarction: a randomized controlled trial |
| Q36546512 | Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease |
| Q37032754 | Escitalopram and enhancement of cognitive recovery following stroke |
| Q38203458 | Factors associated with cognitive decline in transient ischemic attack patients |
| Q36408852 | Guidelines for the treatment of Alzheimer's disease from the Italian Association of Psychogeriatrics |
| Q37396299 | Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review. |
| Q36802613 | Investigational treatment for vascular cognitive impairment |
| Q30945201 | Ischemic brain injury in cerebral amyloid angiopathy |
| Q42373824 | MLC601 in vascular dementia: an efficacy and safety pilot study |
| Q42726370 | Memory loss, behavioral changes, and slurred speech in a 49-year-old man. |
| Q36244982 | Models and mechanisms of vascular dementia |
| Q46839771 | Neural correlates of donepezil-induced cognitive improvement in patients with right hemisphere stroke: a pilot study |
| Q36107249 | Pharmacologic treatment of adolescent and child schizophrenia |
| Q37693772 | Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. |
| Q53377510 | Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine. |
| Q54440823 | Pharmacotherapy for Vascular Cognitive Impairment. |
| Q26865422 | Post-stroke cognitive impairment: epidemiology, mechanisms and management |
| Q36172468 | Poststroke dementia in the elderly. |
| Q34287524 | Preservation of neurons of the nucleus basalis in subcortical ischemic vascular disease |
| Q57821537 | Prevalence and factors associated with memory disturbance and dementia after acute ischemic stroke |
| Q44597506 | Prevalence, resource utilization and costs of vascular dementia compared to Alzheimer's dementia in a population setting |
| Q36439004 | Progress in clinical neurosciences: Canadian guidelines for the development of antidementia therapies: a conceptual summary. |
| Q50856176 | Progression of cognitive impairment in stroke/TIA patients over 3 years. |
| Q33531561 | Promotion of the mind through exercise (PROMoTE): a proof-of-concept randomized controlled trial of aerobic exercise training in older adults with vascular cognitive impairment |
| Q44422345 | Racial/ethnic disparities in medication use among veterans with hypertension and dementia: a national cohort study |
| Q34198750 | Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size |
| Q22242395 | Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline |
| Q58749782 | Repeated Intrastriatal Botulinum Neurotoxin-A Injection in Hemiparkinsonian Rats Increased the Beneficial Effect on Rotational Behavior |
| Q43162002 | Rivastigmine in Chinese patients with subcortical vascular dementia. |
| Q28168730 | Rivastigmine superior to aspirin plus nimodipine in subcortical vascular dementia: an open, 16-month, comparative study |
| Q46766551 | Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease |
| Q34956402 | Screening for cognitive decline following single known stroke using the Mini-Mental State Examination |
| Q35748293 | Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease |
| Q93185032 | Small vessel disease to subcortical dementia: a dynamic model, which interfaces aging, cholinergic dysregulation and the neurovascular unit |
| Q24186591 | Statins for the prevention of dementia |
| Q24241335 | Statins for the prevention of dementia |
| Q38117170 | Strategies to improve recovery in acute ischemic stroke patients: Iberoamerican Stroke Group Consensus |
| Q52351629 | Study protocol for Vitality: a proof-of-concept randomised controlled trial of exercise training or complex mental and social activities to promote cognition in adults with chronic stroke. |
| Q33462283 | Subcortical ischemic cerebrovascular dementia |
| Q36156335 | Subcortical ischemic vascular dementia |
| Q37217996 | The Epidemiology of vascular dementia |
| Q51893815 | The cerebrovascular pathology in Alzheimer's disease and its influence on clinical variables. |
| Q44857974 | The effects of blood pressure and the renin-angiotensin-aldosterone system on regional cerebral blood flow and cognitive impairment in dialysis patients |
| Q42628342 | The long-term efficacy and tolerability of donepezil in patients with vascular dementia |
| Q36806624 | The role of functional assessment as an outcome measure in antidementia treatment |
| Q34552035 | The safety and tolerability of donepezil in patients with Alzheimer's disease |
| Q39286909 | Therapeutic Strategies and Drug Development for Vascular Cognitive Impairment |
| Q36808830 | Therapeutic issues in vascular dementia: studies, designs and approaches |
| Q89699748 | Tianzhi granule improves cognition and BPSD of vascular dementia: a randomized controlled trial |
| Q48118846 | Treatment of Vascular Cognitive Impairment. |
| Q48550601 | Treatment of rest-activity disorders in dementia and special focus on sundowning |
| Q35841746 | Treatment of vascular dementia-evidence from clinical trials with cholinesterase inhibitors |
| Q47128027 | Treatment of vascular dementia. Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology |
| Q80349173 | Treatment of vascular dementia: evidence from epidemiologic studies |
| Q36666426 | Trends in the prevalence and mortality of cognitive impairment in the United States: is there evidence of a compression of cognitive morbidity? |
| Q83194250 | Vascular cognitive impairment |
| Q83640913 | Vascular cognitive impairment |
| Q53339367 | Vascular cognitive impairment. |
| Q34574965 | Vascular cognitive impairment: Current concepts and Indian perspective |
| Q35197111 | Vascular cognitive impairment: disease mechanisms and therapeutic implications |
| Q33967781 | Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association |
| Q57813319 | Vascular dementia |
| Q82010266 | Vascular dementia |
| Q24629003 | Vascular dementia |
| Q36021042 | Vascular dementia. Stroke risk and sequelae define therapeutic approaches |
| Q34659256 | Vascular dementia: a review of recent evidence for prevention and treatment |
| Q37018866 | Vascular dementia: prevention and treatment |
| Q24650263 | Vascular risk factors and dementia: how to move forward? |
| Q36534889 | Weight Loss Associated with Cholinesterase Inhibitors in Individuals with Dementia in a National Healthcare System |
| Q37667316 | White Matter Damage in the Cholinergic System Contributes to Cognitive Impairment in Subcortical Vascular Cognitive Impairment, No Dementia |
| Q37834619 | World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of Alzheimer's disease and other dementias |